Relmada has acquired complete ownership rights to Sepranolone, developed for Tourette syndrome (TS) from Asarina Pharma.

Tourette syndrome is a neurological condition that has no cure but can be managed with various strategies—some of which are ...

The therapy has shown potential in improving TS symptoms in an open-label Phase ... "Relmada acquires Tourette’s therapy rights from Asarina" was originally created and published by ...

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from ...

Phase 2a trials demonstrated Sepranolone's potential to significantly reduce Tourette symptoms and improve quality of life while maintaining a robust safety profile, making it a promising first ...

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled ...

(MENAFN- GlobeNewsWire - Nasdaq) Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB ...

The following is a summary of “Randomized Controlled Trial of the Effects of High-Dose Ondansetron on Clinical Symptoms and Brain Connectivity in Obsessive-Compulsive and Tic Disorders,” published in ...

Tourette syndrome is currently diagnosed about three times more frequently in males than in females. A new study finds that female individuals are less likely to be diagnosed with the syndrome, take ...